The effect of recombinant human interleukin-6 (rhIL-6) on hematopoiesis, biochemical parameters, and other cytokines was evaluated in a phase I-II clinical study in 20 patients with breast cancer or non-small cell lung cancer. The gene discussed is IL6; the disease is non-small cell lung carcinoma.